Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

749
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
749
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

516
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
516

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Donanemab treatment effect by baseline tau burden and disease severity: Observations from the TRAILBLAZER-ALZ 2 trial.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Efficacy and safety of donanemab in the European eligible population: TRAILBLAZER-ALZ 2 post-hoc analyses.

The journal of prevention of Alzheimer's disease·2026
Same author

Generating synthetic tau-PET scans in Alzheimer's disease from MRI, blood biomarkers and demographics with deep learning.

medRxiv : the preprint server for health sciences·2026
Same author

Neuropathological correlates of age and sex differences in 18F-flortaucipir PET.

Brain : a journal of neurology·2026
Same author

Dulaglutide and neurodegeneration biomarkers: REWIND post hoc analysis.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Infusion-related reactions in donanemab-treated participants with early symptomatic Alzheimer's disease.

Alzheimer's & dementia (New York, N. Y.)·2026
Same journal

Breaking barriers: Enhancing access to dementia clinical trials in the United Kingdom-Insights from the Scientific Advisory Board of the Dame Barbara Windsor Dementia Goals Programme.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Unveiling the procoagulant state in Alzheimer's disease: A novel PET imaging strategy.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Estimated labor market outcomes of people progressing from preclinical to early-stage Alzheimer's disease in the United States.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Amyloid exacerbates tau and alpha-synuclein pathologies, behavioral impairments, and neuroinflammation in a mixed dementia model.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Multimorbidity burden and patterns associated with DeepBrainNet-derived brain-age gap in dementia-free older adults: A community-based study.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Reply to "Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities".

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
查看所有相关文章

相关实验视频

Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K

生物标志物 生物标志物

Drew Butkowski1, Ronald B DeMattos2, Sergey Shcherbinin2

  • 1Eli Lilly, Indanapolis, IN, USA.

Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 25, 2025
PubMed
概括
此摘要是机器生成的。

这项研究建立了donanemab生理学基础的药理动力学 (PBPK) 模型,以模拟早期症状性阿尔茨海默病 (AD) 的粉样斑减少. 该模型预测,donanemab治疗有效地通过维持目标间歇性液体 (ISF) 度来降低大脑粉样质斑块水平.

更多相关视频

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

相关实验视频

Last Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

科学领域:

  • 药理动力学和药理动力学
  • 神经退行性疾病 神经退行性疾病
  • 药物开发 药物开发

背景情况:

  • 基于生理学的药理动力学 (PBPK) 模型模拟了抗体治疗药物的处置在中枢神经系统 (CNS),包括脑脊髓 (CSF) 和间歇液体 (ISF).
  • 这些模型可以预测粉样蛋白聚合动态和治疗效果.
  • 多纳尼马布是一种针对N3pGβ-粉样蛋白的IgG1抗体,适用于早期症状性阿尔茨海默病 (AD).

研究的目的:

  • 建立一个与粉样斑块生命周期模型集成的donanemab PBPK模型.
  • 为了确定donanemab的目标ISF度.
  • 预测多纳尼马布剂量方案对大脑粉样质斑块水平的影响.

主要方法:

  • 一个纵向的自然生命周期模型的粉样蛋白聚合被开发为早期症状阿尔茨海默病的参与者.
  • 该模型评估了donanemab在目标ISF度下对粉样蛋白聚合的影响.
  • 分析了多纳尼马布在早期症状AD的第一,第二和第三阶段研究 (N=2560) 的数据.

主要成果:

  • 年龄和APOE4基因型显著影响粉样蛋白聚合,大约在60岁左右,CSF/ISFAβ42和血Aβ42/Aβ40比率下降.
  • 粉样蛋白斑块水平在60岁左右增加,在更高年龄时和,在APOE4载体中较早出现.
  • 在早期有症状的AD患者 (平均年龄73.2岁) 中,当维持血清度>15微克/毫升,与相应的CSF和ISF水平时,多纳尼马布治疗实现了强大的粉样质斑减少.

结论:

  • 了解粉胺向剂的中枢神经系统排放,可以提高对治疗性ISF度的理解.
  • 多纳尼马布PBPK/粉状斑块模型为优化剂量策略提供了一个工具.
  • 这种建模方法支持开发阿尔茨海默病的有效治疗方法.